Pattern recognition receptors and B-cell receptors (PRR/BCR)

Pattern recognition receptors (PRRs) and B-cell receptors (BCRs) are distinct but functionally linked receptor systems essential for the initiation and regulation of immune responses. PRRs, such as Toll-like receptors (TLRs), are primarily expressed on antigen-presenting cells (APCs) like dendritic cells and macrophages, where they detect conserved microbial structures to trigger innate immunity (StatPearls, 2023). BCRs are membrane-bound immunoglobulins on B cells that recognize specific antigens, initiating intracellular signaling cascades required for B-cell activation and antibody production (PubMed, PMC4145244). In therapeutic applications, particularly vaccine design, these receptors are often co-targeted; PRR agonists serve as adjuvants that enhance the adaptive response initiated through the BCR (Nature Reviews Immunology, 2010). Conversely, in B-cell malignancies, inhibitors of the BCR signaling pathway, such as BTK inhibitors, are used to suppress pathological cell proliferation. The coordination between PRR-mediated innate signals and BCR-mediated adaptive signals is a cornerstone of modern immunotherapeutic strategies for infection, cancer, and autoimmune disorders.

Other names

Innate and adaptive immune receptorsTLR and BCR complexAntigen-presenting cell receptorsPRR-BCR signaling axis

Drugs targeting this system typically act by agonizing pattern recognition receptors (PRRs) to provide innate immune activation signals (adjuvancy) while simultaneously or sequentially engaging the B-cell receptor (BCR) to facilitate antigen-specific B-cell activation, proliferation, and differentiation into antibody-secreting plasma cells.